Drugs / EX-527
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04184323 Comparator | Jan 2022 → Dec 2023 | endometriosis, female infertility | Wake Forest University Health Sciences | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EX-527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04184323 ↗ |
| Known as | Selisistat | “EX-527 (Selisistat)” NCT04184323 ↗ |
| Action | Inhibit | “EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1).” NCT04184323 ↗ |
| Modality | Small molecule | “investigate a small molecule inhibitor of SirT1” NCT04184323 ↗ |
| Target | SIRT1 | “EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1).” NCT04184323 ↗ |